Disease burden of bacteraemia with extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales in Korea

C. M. Lee, S. Lee, E. S. Kim, H. B. Kim, W. B. Park, S. M. Moon, Y. K. Kim, K. H. Park, Y. G. Kwak, B. Kim, Y. S. Kim, C. J. Kim, H. Y. Gil, J. Ahn, K. H. Song

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Despite the significant impact of multi-drug-resistant bacteraemia, especially extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) and carbapenem-resistant Enterobacterales (CRE), the burden of disease has not been investigated thoroughly. Aim: To evaluate the clinical outcomes and socio-economic burden of ESBL-E and CRE bacteraemia nationwide in the Republic of Korea. Methods: A search was undertaken for all cases of ESBL-E and CRE bacteraemia and matched controls in 10 hospitals in the Republic of Korea over 6 months. Patients with ESBL-E or CRE bacteraemia were classified as the R group, and matched controls with antibiotic-susceptible bacteraemia and without infection were classified as the S and N groups, respectively. Patients' clinical data were collected, and the economic burden was estimated based on medical expenses, loss of productivity and total costs. Findings: In total, 795 patients were identified, including 265 patients with ESBL-E or CRE bacteraemia and their matched controls. The mean total length of stay for patients with ESBL-E and CRE in the R group was 1.53 and 1.90 times that of patients in the S group, respectively. The 90-day mortality rates for ESBL-E in the R and S groups were 12.1% and 5.6%, respectively, and the corresponding figures for CRE were 28.6% and 12.0%. There were significant differences in the total costs between the R, S and N groups for both ESBL-E and CRE (ESBL-E: $11,151 vs $8712 vs $6063, P=0.004; CRE: $40,464 vs $8748 vs $7279, P=0.024). Conclusion: The clinical and economic burden imposed by ESBL-E or CRE bacteraemia was extremely high. These findings suggest that efforts to control resistant bacteraemia are necessary to reduce this burden.

Original languageEnglish
Pages (from-to)85-93
Number of pages9
JournalJournal of Hospital Infection
StatePublished - Feb 2024

Bibliographical note

Publisher Copyright:
© 2023 The Authors


  • Bacteraemia
  • Carbapenem-resistant Enterobacterales
  • Economic burden
  • Extended-spectrum beta-lactamase
  • Mortality


Dive into the research topics of 'Disease burden of bacteraemia with extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales in Korea'. Together they form a unique fingerprint.

Cite this